1,829 Shares in Ecolab Inc. (ECL) Acquired by Argus Investors Counsel Inc.

Argus Investors Counsel Inc. bought a new position in Ecolab Inc. (NYSE:ECL) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,829 shares of the basic materials company’s stock, valued at approximately $257,000.

A number of other hedge funds also recently modified their holdings of ECL. Wagner Wealth Management LLC bought a new position in Ecolab in the fourth quarter worth approximately $112,000. Signaturefd LLC bought a new position in Ecolab in the first quarter worth approximately $131,000. Ashburton Jersey Ltd raised its position in Ecolab by 302.9% in the fourth quarter. Ashburton Jersey Ltd now owns 1,370 shares of the basic materials company’s stock worth $184,000 after acquiring an additional 1,030 shares during the period. Retirement Income Solutions Inc. bought a new position in Ecolab in the first quarter worth approximately $216,000. Finally, Greenleaf Trust raised its position in Ecolab by 540.7% in the first quarter. Greenleaf Trust now owns 1,730 shares of the basic materials company’s stock worth $237,000 after acquiring an additional 1,460 shares during the period. Institutional investors own 75.95% of the company’s stock.

Get Ecolab alerts:

Several research analysts have weighed in on the stock. Nomura increased their price target on shares of Ecolab from $136.00 to $146.00 and gave the stock a “neutral” rating in a research report on Thursday, June 28th. Credit Suisse Group increased their price target on shares of Ecolab from $137.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 2nd. JPMorgan Chase & Co. downgraded shares of Ecolab from an “overweight” rating to a “neutral” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Ecolab from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Thursday, May 3rd. Finally, Deutsche Bank increased their price target on shares of Ecolab to $140.00 and gave the stock a “hold” rating in a research report on Tuesday, May 8th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $145.44.

Shares of ECL stock traded down $2.10 on Thursday, hitting $141.90. 1,148,900 shares of the stock traded hands, compared to its average volume of 1,276,900. The company has a market capitalization of $41.47 billion, a price-to-earnings ratio of 30.26, a PEG ratio of 2.11 and a beta of 1.00. Ecolab Inc. has a 52 week low of $125.74 and a 52 week high of $150.46. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.15 and a quick ratio of 0.77.

Ecolab (NYSE:ECL) last announced its quarterly earnings data on Tuesday, May 1st. The basic materials company reported $0.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.02. The firm had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.38 billion. Ecolab had a net margin of 10.62% and a return on equity of 19.01%. The company’s revenue was up 9.8% on a year-over-year basis. During the same period last year, the firm earned $0.80 EPS. equities research analysts expect that Ecolab Inc. will post 5.39 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 16th. Stockholders of record on Tuesday, June 19th were given a dividend of $0.41 per share. The ex-dividend date of this dividend was Monday, June 18th. This represents a $1.64 annualized dividend and a dividend yield of 1.16%. Ecolab’s payout ratio is 34.97%.

Ecolab Company Profile

Ecolab Inc provides water, hygiene, and energy technologies and services for customers worldwide. The company operates through Global Industrial, Global Institutional, and Global Energy segments. The Global Industrial segment provides water treatment and process applications, and cleaning and sanitizing solutions primarily to large industrial customers within the manufacturing, food and beverage processing, chemical, mining and primary metals, power generation, pulp and paper, and commercial laundry industries.

Featured Article: Short Selling Stocks, A Beginner��s Guide

Berkshire Hathaway shares jump after Warren Buffett loosens policy on stock buybacks

Berkshire Hathaway Inc on Tuesday eliminated a restriction on its ability to buy back its own stock, a change that could help billionaire Chairman Warren Buffett deploy more of the conglomerate's cash.

The new policy approved by Berkshire's board lets Buffett and Vice Chairman Charlie Munger authorize buybacks when both believe the repurchase price is "below Berkshire's intrinsic value," a determination that would be made "conservatively."

Berkshire's old policy said repurchase prices would not exceed 1.2 times book value per share, or assets minus liabilities.

The new policy is a major change for Berkshire, where Buffett has faced pressure to deploy more than $108 billion of cash and equivalents.

Berkshire's Class A shares closed Tuesday at $288,500, roughly 1.37 times its $211,184 book value per share as of March 31.

The Class B shares rose 2 percent in premarket trading Wednesday, following the announcement of the new policy.

"It's a somewhat significant change," said Steven Check, president of Check Capital Management Inc in Costa Mesa, California. Berkshire shares comprise about 20 percent of its $1.5 billion of assets.

"This is a good thing in an environment where Berkshire has a lot of excess cash, nothing to buy, and an underpriced stock," Check said.

Berkshire raised its repurchase threshold to 1.2 times book value from 1.1 times in December 2012.

The Omaha, Nebraska-based company spent $1.3 billion on share repurchases that month, mainly from the estate of a longtime shareholder. Berkshire has not disclosed any subsequent repurchases under its program.

Known as a bargain-hunter, Buffett has struggled to add large companies to Berkshire's stable of more than 90 businesses in the insurance, railroad, energy, retail and other sectors.

In recent months, he has used some cash to build a more than $40 billion stake in iPhone maker Apple Inc.

At Berkshire's annual meeting in May, Buffett resisted issuing a special dividend to shareholders, while supporting Apple's move to increase its own buybacks, saying that could boost the stock's value.

Munger, for his part, warned that some companies use repurchases simply to prop up their own stock prices.

Berkshire said it would not buy back stock under its new policy until it releases second-quarter results, scheduled for Aug. 3.

It also maintained it will not allow repurchases to reduce its cash and equivalents below $20 billion.

Procter & Gamble shares downgraded by UBS because of rising inflation

Procter & Gamble's profitability will suffer because of rising costs and product pricing pressure, according to UBS.

The firm lowered its rating for Procter & Gamble shares to neutral from buy, predicting the company will report earnings below expectations in its next fiscal year.

��Near-term we are cautious that P&G is likely to guide FY19 earnings below Consensus �� due to higher inflation and ongoing price/trade spend investments,�� analyst Steven Strycula said in a note to clients Wednesday. ��Longer term, we are hopeful P&G's $10bn cost plan and new employee incentive plan can reverse trends in underperforming categories but note this path may require P&G to pierce price bubbles where excessive gaps exist.��

The company��s stock is down 0.9 percent Thursday.

Strycula reaffirmed his $83 price target for Procter & Gamble shares, representing 5 percent upside to Wednesday��s close.

��Given current inflation rates and category price battles we recommend investors wait for a cheaper P&G entry point and for Street ests to fall lower,�� he said.

The analyst estimates the company will generate fiscal 2019 earnings per share of $4.25 versus the Wall Street consensus of $4.43.

Procter & Gamble shares are underperforming the market this year. The stock declined 14 percent year to date through Wednesday compared with the S&P 500's 5 percent gain.

The company did not immediately respond to a request for comment.

Disclaimer

The Picture for Cara Therapeutics Just Got Clearer

Shareholders of small-cap biotech Cara Therapeutics (NASDAQ:CARA) have had a bumpy ride the last couple of years. Hopes were flying high in early 2017, only to be dashed about a year ago by a failed trial of the only drug in its clinical pipeline. But developments in recent weeks have removed some uncertainty for investors, along with the risk that goes with it. In fact, the path forward has never been clearer for the company.

Cara is developing CR845, recently named Korsuva, to treat pain and pruritus (severe itching). It is an opioid, but is differentiated from drugs like morphine or fentanyl by the fact that it attaches to a different type of opioid receptor in the periphery of the body, at the origin of pain or itching, rather than working in the central nervous system. It also doesn't easily cross the blood-brain barrier, and therefore doesn't have the addiction potential and side effects of today's opioids.

The company has tested the drug in indications for acute pain, chronic pain, and pruritus. After a failure last year in a test for chronic arthritis pain, the company has pivoted to focus on pruritus associated with chronic kidney disease, where test results have been strongly positive. There are no Food and Drug Administration (FDA) approved medications or standard of care for pruritus, and Korsuva has been�granted a Breakthrough Therapy designation from the FDA, which means the agency will expedite approval of the drug.

Clinical testing is also continuing for acute pain after surgery, but as a second priority.

Image source: Getty Images.

A hefty partner

In May, Cara announced a partnership with�Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) to commercialize Korsuva. The agreement grants VFMCRP a license to sell the drug as an�injection for the treatment of chronic kidney disease associated pruritus (CKD-aP) in dialysis patients worldwide, except for the U.S., Japan, and South Korea. In return, VFMCRP will pay Cara $50 million up front and up to $470 million in milestone and regulatory payments, buy $20 million in newly issued stock at $17 per share, and pay Cara tiered double-digit royalties once the drug is on the market. The deal takes risk out of Cara Therapeutics stock in three ways.

First of all, the agreement is a huge vote of confidence in the eventual success of Korsuva in treating pruritus. VFMCRP is a joint venture between Vifor Pharma Group and Fresenius Medical Care (NYSE:FMS), a $30-billion market cap company that is the worldwide leader in dialysis care. Last year, Fresenius Medical Care treated about 10% of the 3.2 million dialysis patients in the world in 3,752 clinics.�Outside the U.S., the company treated 127,000 patients in what is by far the largest international network of dialysis clinics.

Pruritus is a serious problem for dialysis patients; 60% to 70% of patients in dialysis experience the condition, and nearly 20% get a severe form that is associated with lower survival.�The fact that Fresenius has chosen Cara Therapeutics as its partner for treating the condition and is willing to pay a big price up front for the privilege is a very strong statement about the drug's commercial viability.

Second, the partnership answers the question of how commercialization will be financed.�Going into the year, Cara had enough cash on hand to carry it into the first half of 2019,�but it was clear that wasn't going to be enough to get Korsuva across the finish line for any indication. The cash deal and the small number of shares in the equity sale (for which Fresenius paid a 47% premium over the market price the day before the announcement) accomplished the financing of commercialization with less than 4% share dilution.

Third, the relationship gives the company a way to build momentum for a U.S. launch. Cara still owns full rights for Korsuva in the U.S. for all indications, and worldwide rights for oral formulations of Korsuva. The partnership with VFMCRP gives Cara a ready-made channel to develop domestic sales of the drug.

Fresenius' largest market is the U.S., where it treats about 38% of all dialysis patients. The agreement is for VFMCRP and Cara to jointly promote injectable Korsuva in Fresenius Medical Care clinics in the U.S., with profits being shared equally between the two companies. What's essentially a discount on Korsuva for Fresenius in the U.S. will cost Cara some margin, but should give it a way to rapidly ramp up domestic sales, while it focuses on marketing to the remaining 62% of dialysis patients in other clinics in the country.

A positive result for acute pain

Late in June, Cara Therapeutics announced positive top-line results from its phase 2/3 study of IV Korsuva for post-operative pain. The trial tested two different doses of Korsuva versus placebo in 444 patients who had either undergone ventral hernia surgery or a hysterectomy. The trial achieved statistical significance for the primary endpoint of pain relief within 24 hours for the arm receiving the higher dose. There also was a 73% reduction in vomiting in patients on the higher dose, with a significant reduction in post-operative nausea and vomiting impact scores.

The successful trial is another risk-reducer for the stock, and opens the door for advancing the drug for acute pain indications. With the failure of the chronic pain trial last year, investors faced uncertainty about whether Cara would ever be able to get approval for Korsuva for pain. But the results from this trial would seem to confirm that the drug's pain reduction mechanism is working as expected. Another phase 3 trial will be required, and Cara said it will be consulting with the FDA on the path forward clinically.

But aside from the fact that the drug met the pain reduction endpoint, the reduction in nausea and vomiting may end up being just as important. Post-operative pain is a huge opportunity, with more than 46 million inpatient and 53 million outpatient surgeries performed annually in the U.S. alone. With markets this big comes plenty of competition, and the nausea and vomiting results may enable some differentiation.

Korsuva may actually be anti-emetic (or help suppress vomiting).�Emesis is controlled by the aptly name vomiting center, which is in the fourth ventricle of the brain. The fourth ventricle is outside the blood-brain barrier, so Korsuva reaches it, and the drug may actually have a direct physiological mechanism that is suppressing nausea and vomiting. In a conference call, Cara CEO Derek Chalmers suggested that the drug may be a broad anti-emetic that could have applications beyond the post-surgical setting, such as in treating chemotherapy-induced nausea and vomiting.

What's ahead

In pruritus in hemodialysis patients, Cara has already launched a phase 3 clinical trial in the U.S. and plans to start a pivotal global trial soon.These studies are the shortest path to a commercial launch of Korsuva. They will be paid for by the Fresenius deal, and the earlier one could read out on the primary endpoint in Q2 of next year.�Since the drug has the Breakthrough Therapy designation�from the FDA, an expedited approval process may result in the drug going on the market in late 2019 or early 2020.

Longer term, Cara has a lot of other opportunities for Korsuva related to itching. It has started a phase 2 trial of oral Korsuva for patients in earlier stages of chronic kidney disease and a phase 1 trial for patients with pruritus caused by chronic liver disease, and is working on plans for studying the drug for itching caused by psoriasis. In the U.S. alone, nearly 45 million people are diagnosed with diseases known to trigger pruritus.

In post-operative pain, there may be a longer path to commercialization, as the company has said that it will continue to prioritize the itching indication over pain. Most likely, Cara will form another partnership to advance the drug in this indication, and the announcement of a deal and any encouraging outcome from FDA discussions could provide further impetus to the stock.

Is the stock a buy here?

The stock is hitting 365-day highs now, and there is still no guarantee that the company's only drug in clinical development will make it onto the market. But the stock has been substantially de-risked in the last two months, and I don't think the market has fully recognized that. Shares are still about 23% below their all-time high, which was set in a few, admittedly over-euphoric days last summer. The picture is a lot clearer now, and the failure of the chronic pain trial has turned out not to be so important, with other, lower-risk paths to commercialization unfolding for the company.

Shareholders who got scared out of the stock in the last year missed out on an 88% gain since May 22. With a market capitalization of only $714 million for a company that has a reasonable chance of success in some big opportunities, there is still plenty of upside possible from here. Of course, we won't�really�know how big the opportunity is until we get a clear sense of pricing and market size, but the stock is selling at a discount to previous highs while also having fewer question-marks. That seems like a potential winner to me.

Hackers Are Selling Access to Critical Airport Systems for $10–and That’s Just the

By Chris Mills of BGR.com

Digital security is something that’s on the mind of every company that owns any device more modern than a typewriter these days, and for good reason. A breach of information can be catastrophic for customers and for a business’s reputation, and it’s hard to think of a more appealing target than an airport. Not only do some handle hundreds of flights per day, but also the personal information of hundreds of thousands of passengers.

A new report from McAfee presents troubling research on the prevalence of remote desktop protocol (RDP) attacks, which offer anyone with a Tor connection and a Bitcoin wallet credentials to remotely connect to a system. The research highlights compromised internal systems of an unnamed airport, but the overall message is that remote logins for millions of machines are now a commodity �� and a cheap one at that.

The headline scary thing is that McAfee’s researchers found logins for sale for just $10 that granted access to an airport’s building security (say, door locks) and video surveillance tools, as well as something related to the inter-terminal transit system. The implications are obviously terrifying �� there’s no point in access badges if some guy with a remote desktop session can just unlock the doors �� but what’s worse is how hackers are able to sell the exploits in the first place.

“Attackers simply scan the Internet for systems that accept RDP connections and launch a brute-force attack with popular tools such as, Hydra, NLBrute or RDP Forcer to gain access,” the report says. “These tools combine password dictionaries with the vast number of credentials stolen in recent large data breaches.”

Once they have logins, attackers are able to monetize the system in a variety of ways. Even if the machines don’t have any valuable data on them, hackers can harness hundreds of thousands of vulnerable systems into a “botnet” that can be used to send spam, mine cryptocurrency, or conduct distributed denial of service attacks against specific targets to take websites or services offline.

Dumb compromised machines are their own currency on the worse parts of the internet, and according to this report, the trade is bustling:

The McAfee Advanced Threat Research team looked at several RDP shops, ranging in size from 15 to more than 40,000 RDP connections for sale at Ultimate Anonymity Service (UAS), a Russian business and the largest active shop we researched. We also looked at smaller shops found through forum searches and chats. During the course of our research we noticed that the size of the bigger shops varies from day to day with about 10%.

Of course, some systems might contain user data, such as credit card info or medical data. Unfortunately, as the researchers point out, the kind of “thin” systems that are often deployed for point-of-sale systems or kiosks are also often the most infrequently updated and most vulnerable to RDP attacks, essentially due to the law of probabilities (with so many machines, some will be vulnerable) and laziness.

Ultimately, all’s well that ends well: In this instance, McAfee notified the airport in question, who patched the vulnerabilities and presumably gave their software vendors a stern talking to. But with the volume of compromised systems being sold, it’s a question of when and not if another juicy target becomes available for sale.

24/7 Wall St.
RBC Raises 2018 and 2019 Oil Price Estimates: 6 Top Picks to Buy Now

#MeToo, #TimesUp Movements Drive Corporate Policy Changes

Since last October, more than half (52%) of 150 companies surveyed in June by outplacement firm Challenger, Gray & Christmas have reviewed the corporate policies on sexual harassment. That’s up from about a third (34%) that were surveyed in January.

The more recent survey also indicates that more companies are revising their previous policies. In the January survey, 63% of respondents were comfortable with their policies compared to 42% in the June survey. The recent survey also found that 2% of companies created new policies in June. None did so when surveyed in January.

Challenger, Gray Vice-President Andrew Challenger, said:

Companies are responding to the cultural movement and recognizing that most of this abuse occurred in the workplace. Calls to make the office a safer place and free from any kind of abuse were overwhelming, and seeing companies respond is heartening. Employers reported adding and clarifying reporting avenues and instituting ‘zero tolerance’ and anti-bullying policies when it comes to workplace harassment.

When asked if they had seen any noticeable changes since the beginning of the #MeToo and #TimesUp movements, nearly 55% said they saw no demonstrable behavior changes while 14% said they observed a more “respectful atmosphere.” At 2% of the companies, more women were asking for raises and promotions.

Formal written policies related to office romances dipped slightly from January (57%) to June (51%), and about 9% of companies said they now give managers discretion to handle relations, up from 3% in January.

Nearly 25% of employers require all relationships to be disclosed to the company, up from 17% in the January survey. More than three-quarters (78%) “discourage” dating between a subordinate and a manager and 27% are looking at relationships on a case-by-case basis.

Andrew Challenger commented:

Fewer companies want to take office romances on a case-by-case basis, suggesting employers want to get ahead of potential problems by creating an overarching policy. By prohibiting relationships between managers and subordinates, companies can minimize the power dynamics that could lead to the abuse of a manager’s position.

Banning office romances is not the answer, Challenger also noted: “Attempting to forbid office relationships will only keep those who do begin dating from taking appropriate avenues to ensure professionalism.”

Best Stocks To Watch Right Now

tags:ATRA,PKG,CADC,HUN,TTC,TTGT,

I love talking about investments that can make you lots of money. But you know what I love even more? Simple strategies that can SAVE you lots of money with very little effort.

After all, even the safest investments carry risk. Meanwhile, some money-saving strategies can end up putting a lot more cash in your pockets with absolutely ZERO risk!

Take car insurance. Despite all the commercials and billboards featuring ducks, geckos, and crazy comedian ladies, I hadn��t shopped around in five or six years.

But when we changed up our household��s car assortment �� and our premiums shot up substantially — I decided to see what other carriers could do for me.

At the risk of sounding like an ad, the process literally did take just 15 or 20 minutes with each company I investigated. Yet the savings were massive��

Progressive ended up being 30% cheaper than Liberty Mutual.

Meanwhile, Geico offered the same level of coverage at 58% less cost!

Needless to say, I switched.

Best Stocks To Watch Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors' Opinion:

• [By ]

  Atara BioTherapeutics (Nasdaq: ATRA) is a leading T-cell immunotherapy company located in San Francisco. The company is developing cutting edge treatments for patients with various types of cancer. And the company is on the verge of a major breakthrough by attempting to become the first company with a scalable adoptive cell therapy for cancer �� something no other company has been able to accomplish.

• [By Shane Hupp]

  Atara Biotherapeutics Inc (NASDAQ:ATRA)’s share price traded down 6.6% during mid-day trading on Thursday following insider selling activity. The company traded as low as $46.05 and last traded at $43.40. 22,628 shares were traded during trading, a decline of 96% from the average session volume of 531,533 shares. The stock had previously closed at $46.45.

• [By Joseph Griffin]

  Atara Biotherapeutics (NASDAQ:ATRA) had its price target decreased by Citigroup from $25.00 to $23.00 in a report released on Monday. Citigroup currently has a sell rating on the biotechnology company’s stock.

Best Stocks To Watch Right Now: Packaging Corporation of America(PKG)

Advisors' Opinion:

• [By Asit Sharma]

  One of the most effective tenets of manufacturing is to increase capacity where demand is sustained, and to carefully contract production where demand has dimmed. This summer, Packaging Corp of America (NYSE:PKG) is living by this philosophy, completing a major conversion of the company's No. 3 machine at its Wallula, Washington mill. The machine will be converted from a paper outputting unit to a packaging beast, which CEO Mark Kowlzan describes as a "400,000 ton per year, high performance, 100% virgin kraft linerboard machine."

• [By Ethan Ryder]

  Packaging Co. of America (NYSE: PKG) and Sonoco (NYSE:SON) are both industrial products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

• [By Ethan Ryder]

  Mackay Shields LLC purchased a new position in shares of Packaging Co. of America (NYSE:PKG) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 15,881 shares of the industrial products company’s stock, valued at approximately $1,790,000.

• [By Joseph Griffin]

  Packaging Corp Of America (NYSE:PKG) was the target of some unusual options trading on Wednesday. Stock investors acquired 1,456 call options on the stock. This represents an increase of 804% compared to the average volume of 161 call options.

Best Stocks To Watch Right Now: China Advanced Construction Materials Group, Inc.(CADC)

Advisors' Opinion:

• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday. Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each. Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55. Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months. Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75. STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results. Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday. China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday. YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings. MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings. Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share. Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701. Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings. The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings. Ca
• [By Lisa Levin] Gainers Axovant Sciences Ltd. (NASDAQ: AXON) shares rose 23.7 percent to $1.49. Axovant announced strengthening of management team and completion of organization restructuring which "enhanced capabilities in research and business development" and reduced internal headcount by 43 percent. Mammoth Energy Services, Inc. (NASDAQ: TUSK) shares jumped 19.8 percent to $37.3148. Mammoth Energy’s subsidiary Cobra signed a new $900 million contract to finish the restoration of critical electrical services and support the initial phase of reconstruction of the electrical utility system in Puerto Rico. Acorn International, Inc. (NYSE: ATV) shares gained 19 percent to $34.0201. Acorn shares rose Friday after the company declared a special one-time cash dividend of $14.97 per ADS. DHI Group, Inc. (NYSE: DHX) shares surged 19 percent to $2.20. My Size, Inc. (NASDAQ: MYSZ) climbed 16.8 percent to $1.18 after the company received a Notice of Allowance from the USPTO for measurement technology patent. Global Eagle Entertainment Inc. (NASDAQ: ENT) gained 16.6 percent to $2.32. Leju Holdings Limited (NYSE: LEJU) gained 16.5 percent to $1.34 following Q1 beat. Evolus, Inc. (NASDAQ: EOLS) shares surged 16.5 percent to $26.1499. Evolus named Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development. Jupai Holdings Limited (NYSE: JP) shares gained 15 percent to $26.29 after reporting Q1 results. Momo Inc. (NASDAQ: MOMO) shares gained 15 percent to $44.7702 after the company reported better-than-expected results for its first quarter and issued strong sales forecast for the second quarter. Windstream Holdings, Inc. (NASDAQ: WIN) rose 15 percent to $7.075. China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) gained 14.4 percent to $2.746. American Woodmark Corporation (NASDAQ: AMWD) climbed 14.2 percent to $101.10 after the company reported upbeat Q4 results. Savara Inc. (NAS

Best Stocks To Watch Right Now: Huntsman Corporation(HUN)

Advisors' Opinion:

• [By Taylor Cox]

  Investor Events

  Annual shareholder meetings for MGP Ingredients, Inc (NASDAQ: MGPI) and Fiserv, Inc (NASDAQ: FISV), respectively Huntsman Corporation (NYSE: HUN) investor day

  Thursday

• [By Max Byerly]

  Huntsman (NYSE: HUN) and DSM (OTCMKTS:RDSMY) are both basic materials companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

• [By Andy Pai]

  Three of these were chemical companies: Westrock Co (NYSE: WRK), Olin Corporation (NYSE: OLN), and Huntsman Corporation (NYSE: HUN). In reviewing upside, multiples, and margins, Huntsman looked like the best candidate for a deeper dive.

• [By Logan Wallace]

  Karp Capital Management Corp lifted its stake in shares of Huntsman Corp (NYSE:HUN) by 299.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 66,760 shares of the basic materials company’s stock after purchasing an additional 50,045 shares during the period. Karp Capital Management Corp’s holdings in Huntsman were worth $1,953,000 at the end of the most recent reporting period.

• [By Logan Wallace]

  State Board of Administration of Florida Retirement System cut its stake in Huntsman Co. (NYSE:HUN) by 2.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,289 shares of the basic materials company’s stock after selling 7,276 shares during the quarter. State Board of Administration of Florida Retirement System owned about 0.14% of Huntsman worth $9,690,000 at the end of the most recent quarter.

Best Stocks To Watch Right Now: Toro Company (TTC)

Advisors' Opinion:

• [By Shane Hupp]

  Toro (NYSE:TTC) – Dougherty & Co cut their Q2 2018 earnings per share (EPS) estimates for Toro in a report issued on Tuesday, May 22nd. Dougherty & Co analyst J. Fisher now expects that the company will post earnings of $1.18 per share for the quarter, down from their previous estimate of $1.22.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Toro (TTC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  Toro (NYSE:TTC) last posted its quarterly earnings data on Thursday, May 24th. The company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.18 by $0.02. The firm had revenue of $875.30 million during the quarter, compared to analyst estimates of $901.26 million. Toro had a return on equity of 45.89% and a net margin of 10.08%. Toro’s revenue was up .3% on a year-over-year basis. During the same period in the prior year, the business posted $1.08 EPS. equities research analysts expect that Toro will post 2.71 earnings per share for the current fiscal year.

• [By Lisa Levin] Companies Reporting Before The Bell Best Buy Co., Inc. (NYSE: BBY) is projected to report quarterly earnings at $0.74 per share on revenue of $8.73 billion. McKesson Corporation (NYSE: MCK) is expected to report quarterly earnings at $3.56 per share on revenue of $51.25 billion. Medtronic plc (NYSE: MDT) is estimated to report quarterly earnings at $1.39 per share on revenue of $8.00 billion. Hormel Foods Corporation (NYSE: HRL) is projected to report quarterly earnings at $0.45 per share on revenue of $2.39 billion. Brady Corporation (NYSE: BRC) is expected to report quarterly earnings at $0.49 per share on revenue of $291.47 million. Sanderson Farms, Inc. (NASDAQ: SAFM) is projected to report quarterly earnings at $2.2 per share on revenue of $841.75 million. The Toronto-Dominion Bank (NYSE: TD) is estimated to report quarterly earnings at $1.16 per share on revenue of $6.86 billion. Royal Bank of Canada (NYSE: RY) is expected to report quarterly earnings at $1.61 per share on revenue of $8.05 billion. 58.com Inc. (NYSE: WUBA) is projected to report quarterly earnings at $0.21 per share on revenue of $372.49 million. Luxoft Holding, Inc. (NYSE: LXFT) is estimated to report quarterly earnings at $0.59 per share on revenue of $228.53 million. The Toro Company (NYSE: TTC) is expected to report quarterly earnings at $1.21 per share on revenue of $916.73 million. StealthGas Inc. (NASDAQ: GASS) is projected to report quarterly earnings at $0.06 per share on revenue of $37.75 million. Stage Stores, Inc. (NYSE: SSI) is estimated to report earnings for its first quarter. Thermon Group Holdings, Inc. (NYSE: THR) is projected to report quarterly earnings at $0.2 per share on revenue of $96.24 million. Tuniu Corporation (NASDAQ: TOUR) is estimated to report quarterly loss at $0.03 per share on revenue of $76.72 million.

   

Best Stocks To Watch Right Now: TechTarget, Inc.(TTGT)

Advisors' Opinion:

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on TechTarget (TTGT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on TechTarget (TTGT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  TechTarget (NASDAQ:TTGT) Director Leonard P. Forman sold 63,862 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $23.59, for a total transaction of $1,506,504.58. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Top 10 Small Cap Stocks To Watch For 2019

tags:ACHN,PQ,CNR,FCEL,

On Tuesday, our Under the Radar Movers�newsletter suggested going long on small cap semiconductor stock Pixelworks, Inc (NASDAQ: PXLW):

��There are a couple of things going on with Pixelworks that are prompting this purchase. One of them is the steep low and subsequent reversal from the 9th (marked with an arrow on the chart). All it took for that selloff to turn into a capitulation is a brush with the 200-day moving average line, and ever since then it's been nothing but buying. At the same time, thank to today's high-volume surge, PXLW has broken above a major technical ceiling. While overbought in the short run, there's still a ton of room to reclaim here after the major pullback before the August reversal.��

Our Under the Radar Movers�newsletter has a more thorough�discussion about�Pixelworks�� technical chart and a potential long trading strategy:

Top 10 Small Cap Stocks To Watch For 2019: Achillion Pharmaceuticals Inc.(ACHN)

Advisors' Opinion:

• [By Lisa Levin] Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 29.4 percent to $5.50 in pre-market trading after the company disclosed that its first pivotal Phase 3 trial of IV tramadol achieved the primary and key secondary endpoints. MB Financial, Inc. (NASDAQ: MBFI) rose 16.8 percent to $51.00 in pre-market trading. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock. LiveXLive Media, Inc. (NASDAQ: LIVX) rose 9.3 percent to $5.40 in pre-market trading after falling 28.92 percent on Friday. Celyad SA (NASDAQ: CYAD) shares rose 9 percent to $29.30 in pre-market trading after climbing 3.26 percent on Friday. Ethan Allen Interiors Inc. (NYSE: ETH) rose 6.7 percent to $26.40 in pre-market trading after gaining 1.64 percent on Friday. Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 5.4 percent to $3.90 in pre-market trading after gaining 3.06 percent on Friday. Acacia Communications, Inc. (NASDAQ: ACIA) rose 5.2 percent to $34.70 in pre-market trading after gaining 1.38 percent on Friday. Westinghouse Air Brake Technologies Corporation (NYSE: WAB) rose 5.1 percent to $100 in pre-market trading. General Electric Company (NYSE: GE) agreed to merge its transportation unit with Wabtec. Sunrun Inc. (NASDAQ: RUN) shares rose 4.7 percent to $11.50 in pre-market trading. Nasdaq, Inc. (NASDAQ: NDAQ) shares rose 4.3 percent to $93.98 in the pre-market trading session. LaSalle Hotel Properties (NYSE: LHO) shares rose 4.2 percent to $33.25 in pre-market trading. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported. Monro, Inc. (NASDAQ: MNRO) shares rose 4 percent to $58.35 in pre-market trading as the company posted upbeat quarterly earnings and disclosed that it has acquired Free Service Tire. HUYA Inc. (NYSE: HUYA) rose 3.7 percent to $19.75 in pre-market trading after falling 4.80 percent on Friday.

  Find out what's going

• [By Shane Hupp]

  News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.941587509483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

• [By Ethan Ryder]

  Achillion Pharmaceuticals (NASDAQ:ACHN) – Research analysts at B. Riley reduced their FY2018 EPS estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday, May 2nd. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will earn ($0.58) per share for the year, down from their previous estimate of ($0.55). B. Riley has a “Neutral” rating and a $3.50 price objective on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.71) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.84) EPS.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Keith Speights]

  Skeptics might deride a comparison of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) as an exercise in finding the biggest loser. Both companies continue to post huge net losses every quarter, and their stocks are down by at least 30% over the last 12 months.

• [By Stephan Byrd]

  Achillion Pharmaceuticals (NASDAQ:ACHN) has been given an average recommendation of “Hold” by the nine brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $5.20.

Top 10 Small Cap Stocks To Watch For 2019: Petroquest Energy Inc(PQ)

Advisors' Opinion:

• [By Ethan Ryder]

  News headlines about Petroquest Energy (NYSE:PQ) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petroquest Energy earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the energy company an impact score of 47.638327846877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Top 10 Small Cap Stocks To Watch For 2019: China Metro-Rural Holdings Limited(CNR)

Advisors' Opinion:

• [By Joseph Griffin]

  Shares of Canadian National Railway (TSE:CNR) (NYSE:CNI) have been given an average recommendation of “Buy” by the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is C$109.36.

• [By Shane Hupp]

  Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its position in Canadian National Railway (NYSE:CNI) (TSE:CNR) by 21.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,400 shares of the transportation company’s stock after selling 522,300 shares during the period. Canadian National Railway accounts for about 1.7% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 7th biggest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.27% of Canadian National Railway worth $184,215,000 at the end of the most recent reporting period.

• [By Ethan Ryder]

  State of Tennessee Treasury Department lessened its stake in shares of Canadian National Railway (NYSE:CNI) (TSE:CNR) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 842,775 shares of the transportation company’s stock after selling 13,507 shares during the quarter. State of Tennessee Treasury Department owned about 0.11% of Canadian National Railway worth $61,565,000 as of its most recent filing with the SEC.

Top 10 Small Cap Stocks To Watch For 2019: FuelCell Energy Inc.(FCEL)

Advisors' Opinion:

• [By Logan Wallace]

  FuelCell Energy (NASDAQ: FCEL) and HRG Group (NYSE:HRG) are both oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

• [By Shane Hupp]

  FuelCell Energy (NASDAQ: FCEL) is one of 25 public companies in the “Miscellaneous electrical machinery, equipment, & supplies” industry, but how does it contrast to its peers? We will compare FuelCell Energy to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.

• [By Shane Hupp]

  FuelCell Energy Inc (NASDAQ:FCEL) shares traded up 5.8% on Friday . The stock traded as high as $1.49 and last traded at $1.45. 12,581,855 shares traded hands during trading, an increase of 983% from the average session volume of 1,161,380 shares. The stock had previously closed at $1.37.

• [By Paul Ausick]

  FuelCell Energy Inc. (NASDAQ: FCEL) posted an increase of 17.8% in short interest during the period. Some 6.9 million shares were short as of May 15. The stock closed at $1.88 on Thursday, down about 1.1% for the day, in a 52-week range of $0.93 to $2.49. Shares traded up about 1.4% in the short interest period, and days to cover rose from eight to 14.

• [By Paul Ausick]

  FuelCell Energy Inc. (NASDAQ: FCEL) posted a decrease of 25.7% in short interest during the period. Some 5.86 million shares were short as of April 30. The stock closed at $1.93 on Wednesday, up about 1.6% for the day, in a 52-week range of $0.80 to $2.49. Shares traded down about 7.8% in the short interest period, and days to cover rose from six to eight.

China Automotive Systems (CAAS) Earns Daily Media Impact Score of 0.04

Media coverage about China Automotive Systems (NASDAQ:CAAS) has been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. China Automotive Systems earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media stories about the auto parts company an impact score of 45.9702420023483 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of CAAS opened at $4.11 on Friday. The company has a market cap of $128.79 million, a price-to-earnings ratio of 6.42 and a beta of 2.10. China Automotive Systems has a 52 week low of $4.04 and a 52 week high of $5.90.

Get China Automotive Systems alerts:

China Automotive Systems (NASDAQ:CAAS) last issued its quarterly earnings data on Thursday, May 10th. The auto parts company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.04). The company had revenue of $134.02 million for the quarter, compared to the consensus estimate of $122.81 million. China Automotive Systems had a positive return on equity of 5.83% and a negative net margin of 4.03%. sell-side analysts predict that China Automotive Systems will post 0.69 earnings per share for the current fiscal year.

A number of brokerages recently commented on CAAS. Zacks Investment Research raised China Automotive Systems from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine lowered China Automotive Systems from a “buy” rating to a “hold” rating in a research report on Friday, June 1st.

China Automotive Systems Company Profile

China Automotive Systems, Inc, through its subsidiaries, manufactures and sells automotive systems and components in the People's Republic of China. The company produces rack and pinion power steering gears for cars and light duty vehicles; integral power steering gears for heavy-duty vehicles; power steering parts for light duty vehicles; sensor modules; automobile steering systems and columns; and automobile electronic systems and parts.

BWX Technologies (BWXT) Earns Daily Media Impact Rating of 0.11

News coverage about BWX Technologies (NYSE:BWXT) has trended somewhat positive on Friday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BWX Technologies earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the technology company an impact score of 44.8987761555585 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of NYSE BWXT traded down $0.12 during mid-day trading on Friday, hitting $62.83. The stock had a trading volume of 6,261 shares, compared to its average volume of 545,755. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 1.37. BWX Technologies has a 1 year low of $48.48 and a 1 year high of $72.18. The company has a market cap of $6.28 billion, a price-to-earnings ratio of 30.64, a PEG ratio of 2.24 and a beta of 0.48.

Get BWX Technologies alerts:

BWX Technologies (NYSE:BWXT) last issued its earnings results on Friday, May 4th. The technology company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.61 by $0.06. BWX Technologies had a net margin of 9.24% and a return on equity of 72.41%. The company had revenue of $457.00 million for the quarter, compared to the consensus estimate of $447.20 million. During the same period in the previous year, the firm earned $0.55 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. equities research analysts anticipate that BWX Technologies will post 2.56 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 6th. Investors of record on Friday, May 18th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend was Thursday, May 17th. BWX Technologies’s payout ratio is 31.22%.

Several research firms have commented on BWXT. ValuEngine raised shares of BWX Technologies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 19th. SunTrust Banks lifted their price target on shares of BWX Technologies to $89.00 and gave the stock a “buy” rating in a research note on Friday, May 4th. Barclays began coverage on shares of BWX Technologies in a research note on Thursday, March 29th. They set an “underweight” rating and a $62.00 price target on the stock. Drexel Hamilton reissued a “buy” rating and set a $78.00 price target on shares of BWX Technologies in a research note on Thursday, June 21st. Finally, Credit Suisse Group decreased their price target on shares of BWX Technologies from $72.00 to $64.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $71.78.

In related news, insider Joseph G. Henry sold 7,774 shares of BWX Technologies stock in a transaction on Friday, June 8th. The shares were sold at an average price of $66.60, for a total value of $517,748.40. Following the sale, the insider now owns 10,639 shares in the company, valued at $708,557.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David S. Black sold 1,000 shares of BWX Technologies stock in a transaction on Wednesday, April 11th. The shares were sold at an average price of $65.10, for a total transaction of $65,100.00. Following the completion of the sale, the chief financial officer now owns 70,874 shares in the company, valued at approximately $4,613,897.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,774 shares of company stock worth $717,388. 0.76% of the stock is owned by insiders.

BWX Technologies Company Profile

BWX Technologies, Inc manufactures and sells nuclear components to the United States government. The company operates in three segments: Nuclear Operations, Technical Services, and Nuclear Energy. The Nuclear Operations segment offers precision naval nuclear components and reactors; close-tolerance and equipment for nuclear applications; and components for defense applications, as well as critical nuclear components, fuels, and assemblies for government and other uses.

Lewis Cirne Sells 89,000 Shares of New Relic Inc (NEWR) Stock

New Relic Inc (NYSE:NEWR) CEO Lewis Cirne sold 89,000 shares of the stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $101.65, for a total value of $9,046,850.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lewis Cirne also recently made the following trade(s):

Get New Relic alerts: On Monday, June 4th, Lewis Cirne sold 89,000 shares of New Relic stock. The shares were sold at an average price of $104.65, for a total value of $9,313,850.00. On Wednesday, May 2nd, Lewis Cirne sold 89,000 shares of New Relic stock. The shares were sold at an average price of $71.11, for a total value of $6,328,790.00.

New Relic traded down $1.60, reaching $101.01, during trading hours on Tuesday, MarketBeat Ratings reports. 444,300 shares of the company’s stock were exchanged, compared to its average volume of 675,691. New Relic Inc has a twelve month low of $42.69 and a twelve month high of $111.59. The company has a market cap of $5.58 billion, a P/E ratio of -136.50 and a beta of 0.84.

New Relic (NYSE:NEWR) last issued its quarterly earnings results on Tuesday, May 8th. The software maker reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.04. New Relic had a negative return on equity of 20.14% and a negative net margin of 12.76%. The firm had revenue of $98.40 million during the quarter, compared to the consensus estimate of $96.34 million. During the same period last year, the business posted ($0.11) EPS. The business’s revenue was up 34.2% compared to the same quarter last year. analysts forecast that New Relic Inc will post -0.59 earnings per share for the current fiscal year.

A number of analysts recently weighed in on the company. Robert W. Baird increased their price objective on New Relic from $88.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, June 5th. Wedbush restated an “outperform” rating and issued a $86.00 price objective (down from $93.00) on shares of New Relic in a report on Wednesday, May 9th. Morgan Stanley increased their price objective on New Relic from $61.00 to $67.00 and gave the company an “equal weight” rating in a report on Wednesday, May 9th. Zacks Investment Research downgraded New Relic from a “buy” rating to a “hold” rating in a report on Friday, March 9th. Finally, Needham & Company LLC increased their price objective on New Relic from $73.00 to $84.00 and gave the company a “buy” rating in a report on Monday, April 2nd. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. New Relic presently has an average rating of “Buy” and a consensus price target of $90.50.

A number of institutional investors have recently modified their holdings of NEWR. Stratos Wealth Partners LTD. acquired a new stake in shares of New Relic in the 1st quarter valued at about $141,000. Stifel Financial Corp acquired a new stake in shares of New Relic in the 1st quarter valued at about $203,000. Quantum Capital Management acquired a new stake in shares of New Relic in the 1st quarter valued at about $210,000. Commonwealth Equity Services LLC acquired a new stake in shares of New Relic in the 1st quarter valued at about $212,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of New Relic in the 4th quarter valued at about $233,000. Hedge funds and other institutional investors own 74.08% of the company’s stock.

New Relic Company Profile

New Relic, Inc, a software-as-a-service company, provides various digital products worldwide. Its cloud-based platform and suite of products include New Relic Platform, which enable organizations to collect, store, and analyze data. The company offers New Relic Application Performance Management that provides visibility into the performance and usage of server-based applications, such as data pertaining to response time, transaction throughput, error rates, top transactions, and user satisfaction; New Relic Mobile, which provides code-level visibility into the performance and health of mobile applications running on the iOS and Android mobile operating systems; and New Relic Browser that monitors the page view experiences of actual end-users for desktop and mobile browser-based applications.